One of the few companies manufacturing both hMSC and hNSC
SCF activity preserved through patented technology for 3 years
MSCs approved as a treatment of AMI in Kazakhstan
First FDA-approved clinical trial using stem cells to treat Alzheimer’s
Producing clinical-grade stem cells with strong activity in large scale
About Us
Jiuzhitang Meike (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as Jiuzhitang Meike) was established in March 2018 with a registered capital of 0.2 billion yuan. It is a biotechnology company focusing on the production, research and development and sales of stem cell drugs and regenerative medicine products. Jiuzhitang Meike has built a large-scale stem cell drug research and development and production base in Beijing Daxing Biomedical Base, China Pharmaceutical Valley, which meets the GMP standards of China, the United States and the European Union. The office production area is about 4800m ², and the production platform is equipped with four independent B- Class A clean areas, which can produce clinical-grade stem cell drugs that meet the requirements of drug declaration in China and the United States.
Technical advantages
Clinical Indications
In the US, Stemedica and its partners have launched 8 clinical trials using stem cells to treat ischemic stroke, skin photoaging, non-ischemic chronic heart failure, Alzheimer’s disease, traumatic brain injury, heart failure requiring LVAD, acute myocardial infarction and lung injury caused by COVID-19. Trials on ischemic stroke and chronic heart failure have completed Phase IIa and published many high level academic papers, while the one on Alzheimer’s is the first US study with approval to treat this debilitating disorder using stem cells. In addition, Stemedica has 11 clinical studies in progress in Switzerland, Kazakhstan, Mexico, China, etc. In particular, the Kazak study treating acute heart failure with Stemedica manufactured it-hMSCs has completed, rendering the product being approved and listed by the Ministry of Health of Kazakhstan as a therapy to this disease in September 2018.
Acute myocardial infarction
Acute myocardial infarction is myocardial necrosis caused by acute, persistent ischemia and hypoxia in...
Chronic heart failure
Chronic heart failure lies in the end stage of development of many cardiovascular diseases...
Cerebral stroke
Commonly known as apoplexy, cerebral stroke is the second most common cause of death and..
Alzheimer's disease
Alzheimer's disease, commonly known as senile dementia, is a common neurodegenerative ...
Traumatic brain/spinal injury
Traumatic brain/spinal injury is a penetrating injury mainly caused by traffic accidents, work...
Cutaneous photoaging
Skin aging is a series of complex biological changes that involve both endogenous and ...
Advisors
Jiuzhitang Maker is supported by global expertise in areas of stem cells research and development of clinical programs on pharmaceuticals. Dr. Nikolai Tankovich is a recognized innovator, researcher and educator for laser applications in medicine, cancer vaccines, stem cell therapies and other medical related disciplines. Dr. Alex Kharazi is a distinguished expert on cell therapy and immunotherapy. He has been a faculty member at the University of Southern California in Los Angeles and Chief Scientist at an Immunotherapy Laboratory......
Dr. Tankovich holds a Master of Science degree in Plasma Physics from Moscow University, an M.D. from Semashco Medical University (Moscow), and a Ph.D. in BioPhysics from Lomonosov Moscow University. He is a recognized innovator, researcher and educator for laser applications in medicine, cancer vaccines, stem cell therapies and other medical related disciplines. As founder and director of several corporations, Dr. Tankovich has more than 100 US and other foreign patents issued and pending, and has published over 60 articles on well-known academic journals.
Dr. Kharazi finished Medical School in 1978 in Kiev, Ukraine, where he earned his medical degree in internal medicine and pathology. From 1978 to 1981, he was a post-doctoral fellow at the Kiev Institute of Gerontology. Dr. Kharazi was one of the first to discover the inhibitory effects of old thymus in mice and later published over 30 papers on this subject. He is a faculty member at the University of Southern California in Los Angeles, and a named inventor of 8 US patents and various foreign patents.
Dr. Verkh has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, neurology, peripheral vascular diseases, hematology, blood disorders and imaging methods. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. Under his leadership, Stemedica obtained several INDs for clinical trials in the United States and emergency INDs from the FDA.
Company News
Copyright: Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
